Fce fusion proteins for treatment of allergy and asthma
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Apr 29, 2004
filing date -
Jun 15, 2001
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present invention includes Fc.epsilon. fragments conjugated with FC.gamma. fragments, for example, Fc.epsilon.1-Hinge-FcE2-FcE3-FcE4-FCy; Hinge-FcE2-FcE3-FcE4-Fcy; FC.epsilon.2-Fc.epsilon.3-Fc.epsilon.4-FC.gamma-.; FC.epsilon.2-Fc.epsilon.3-Fc.gamma.; FC.epsilon.3-Fc.gamma.; and FC.epsilon.3-Fc.epsilon.4-FC.gamma., or any derivative or peptide, which has equivalent immunological function. The Fc.gamma. fragment may be a fragment of any of the IgG subclasses (IgG1 I IgG2, IgG3, or IgG4), preferably IgG1 or IgG3, wherein the fragment binds Fc.gamma.RIIB. The present invention also includes compositions suitable for administering to a patient suffering from an allergic disease comprising the fusion protein construct in a pharmaceutical composition including, for example, an excipient, diluant, or carrier. This treatment may be combined with anti-IgE therapy or allergen immunotherapy.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully